 BRCA2 Protein
"BRCA2 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)
| Descriptor ID |
D024682
|
| MeSH Number(s) |
D12.776.313.249 D12.776.624.776.101 D12.776.660.105
|
| Concept/Terms |
BRCA2 Protein- BRCA2 Protein
- FANCD1 Protein
- Fanconi Anemia Complementation Group D1 Protein
- Fanconi Anemia Group D1 Protein
- BRCA2 Gene Product
- Breast Cancer 2 Gene Product
- Fanconi Anemia Group D1 Complementing Protein
- Breast Cancer 2 Protein
|
Below are MeSH descriptors whose meaning is more general than "BRCA2 Protein".
Below are MeSH descriptors whose meaning is more specific than "BRCA2 Protein".
This graph shows the total number of publications written about "BRCA2 Protein" by people in this website by year, and whether "BRCA2 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2008 | 2 | 0 | 2 | | 2009 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 | | 2013 | 0 | 1 | 1 | | 2014 | 1 | 0 | 1 | | 2015 | 1 | 1 | 2 | | 2016 | 2 | 0 | 2 | | 2017 | 2 | 1 | 3 | | 2018 | 0 | 1 | 1 | | 2019 | 2 | 1 | 3 | | 2020 | 2 | 3 | 5 | | 2021 | 3 | 1 | 4 | | 2022 | 0 | 4 | 4 | | 2023 | 0 | 2 | 2 | | 2024 | 2 | 4 | 6 | | 2025 | 1 | 1 | 2 | | 2026 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "BRCA2 Protein" by people in Profiles.
-
Buckley KH, Dungan ME, Dinh K, Kelly GM, Hausler R, Bennett KE, Clay DG, Youngman JE, Majer AD, Beyries KA, Niccum BA, Shaffer SM, Karakasheva TA, Hamilton KE, Kochman ML, Ginsberg GG, Ahmad N, Maxwell KN, Katona BW. Gastric Epithelium from BRCA1 and BRCA2 Carriers Harbors Increased Double-Stranded DNA Damage and Enhanced Growth Potential. Mol Cancer Res. 2026 Jul 02; 24(7):589-600.
-
Graham LS, Yu EY. Early and Precise: Treating HRR Alterations in Hormone-Sensitive Prostate Cancer. Clin Cancer Res. 2025 Oct 01; 31(19):4001-4003.
-
Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, Bonnefoi H, Knudsen E, Im SA, DeMichele A, Van't Veer L, Kim SB, Bear H, McCarthy N, Rhiem K, Turner N, Witkiewicz A, Rojo F, Filipits M, Martin LA, Fasching PA, Schem C, Becker K, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Liu Y, Valota O, Felder B, Weber K, Nekljudova V, Loibl S. BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis. JCO Precis Oncol. 2025 Apr; 9:e2400742.
-
Lakritz S, Nicklawsky A, Alami V, Kohli M, Moskaluk C, Riedlinger G, Salhia B, Singer EA, Naqash AR, Nepple K, Edge S, Myint Z, Kolesar J, Adra N, Flaig T, Graham LS. Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations. Clin Genitourin Cancer. 2025 Feb; 23(1):102293.
-
Richardson DL, Quintanilha JCF, Danziger N, Li G, Sokol E, Schrock AB, Ebot E, Bhardwaj N, Norris T, Afghahi A, Frachioni A, Washington C, Dockery L, Elvin J, Graf RP, Moore KN. Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice. Clin Cancer Res. 2024 Oct 15; 30(20):4644-4653.
-
Liu W, Cao H, Wang J, Elmusrati A, Han B, Chen W, Zhou P, Li X, Keysar S, Jimeno A, Wang CY. Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma. Nat Commun. 2024 08 08; 15(1):6755.
-
Iwanaga R, Yamamoto TM, Gomez K, Nguyen LL, Woodruff ER, Post MD, Mikeska RG, Danis E, Danhorn T, Boorgula MP, Mitra SS, Marjon NA, Bitler BG, Brubaker LW. Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma. Cancer Res Commun. 2024 08 01; 4(8):1919-1932.
-
Niccum BA, Coughlin S, Clay D, Heiman J, Buckley KH, Dungan M, Daniel MG, Ruiz J, Maxwell KN, Domchek SM, Leung G, Ahmad NA, Ginsberg GG, Kochman ML, Katona BW. Prevalence of H. pylori and Gastric Intestinal Metaplasia in BRCA1 and BRCA2 Carriers. Cancer Prev Res (Phila). 2024 Jul 02; 17(7):305-309.
-
Zhang Z, Ye S, Bernhardt SM, Nelson HD, Velie EM, Borges VF, Woodward ER, Evans DGR, Schedin PJ. Postpartum Breast Cancer and Survival in Women With Germline BRCA Pathogenic Variants. JAMA Netw Open. 2024 04 01; 7(4):e247421.
-
Köbel M, Yang RZ, Kang EY, Al-Shamma Z, Cook LS, Kinloch M, Carey MS, Hopkins L, Nelson GS, McManus KJ, Vizeacoumar FS, Vizeacoumar FJ, Freywald A, Fu Y, Reuss DE, Lee CH. Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas. Gynecol Oncol. 2023 11; 178:80-88.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|